[go: up one dir, main page]

MA30648B1 - Methode de criblage de composes aux proprietes anti-amyloide. - Google Patents

Methode de criblage de composes aux proprietes anti-amyloide.

Info

Publication number
MA30648B1
MA30648B1 MA31641A MA31641A MA30648B1 MA 30648 B1 MA30648 B1 MA 30648B1 MA 31641 A MA31641 A MA 31641A MA 31641 A MA31641 A MA 31641A MA 30648 B1 MA30648 B1 MA 30648B1
Authority
MA
Morocco
Prior art keywords
screening compounds
amyloid
compounds
properties
amyloid properties
Prior art date
Application number
MA31641A
Other languages
English (en)
Inventor
Hoau-Yan Wang
Philippe Morain
Caryn Thibierge
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA30648B1 publication Critical patent/MA30648B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

METHODE DE CRIBLAGE DE COMPOSES AUX PROPRIETES ANTI-AMYLOIDE L'invention concerne une méthode de criblage de composés aux propriétés anti-amyloïde. La méthode de criblage de composés ayant l'aptitude de dissocier ou prévenir des complexes de forte affinité entre les peptides (beta)-amyloïde et les récepteurs nicotiniques de l'acétylcholine de tissus de cortex humains permet d'identifier rapidement des composés destinés au traitement curatif et/ou préventif des maladies neurodégénératives et de la maladie d'Alzheimer en particulier.
MA31641A 2006-08-18 2009-02-13 Methode de criblage de composes aux proprietes anti-amyloide. MA30648B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0607385A FR2905009A1 (fr) 2006-08-18 2006-08-18 Methode de criblage de composes aux proprietes anti-amyloide

Publications (1)

Publication Number Publication Date
MA30648B1 true MA30648B1 (fr) 2009-08-03

Family

ID=38157874

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31641A MA30648B1 (fr) 2006-08-18 2009-02-13 Methode de criblage de composes aux proprietes anti-amyloide.

Country Status (14)

Country Link
US (1) US20100197740A1 (fr)
EP (1) EP2051994A1 (fr)
JP (1) JP2010505089A (fr)
KR (1) KR20090047532A (fr)
CN (1) CN101506231A (fr)
AU (1) AU2007285666A1 (fr)
BR (1) BRPI0715890A2 (fr)
CA (1) CA2661122A1 (fr)
EA (1) EA200900149A1 (fr)
FR (1) FR2905009A1 (fr)
MA (1) MA30648B1 (fr)
MX (1) MX2009001591A (fr)
NO (1) NO20090769L (fr)
WO (1) WO2008020131A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN105669597B (zh) * 2009-12-10 2019-05-07 加利福尼亚大学董事会 淀粉状蛋白结合剂
JP2013537912A (ja) 2010-09-23 2013-10-07 アッヴィ・インコーポレイテッド アザアダマンタン誘導体の一水和物
JP6566867B2 (ja) * 2012-07-13 2019-08-28 ペイン セラピューティクス インコーポレイテッド 生きている患者でのアルツハイマー病アッセイ
SG11201903725UA (en) 2016-11-25 2019-05-30 Shine Biopharma Inc Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
EA038404B1 (ru) * 2017-03-22 2021-08-23 Дженув Инк. Применение траметиниба для лечения нейродегенеративного заболевания, вызванного утратой или повреждением нейронов

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009370A1 (fr) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Liberation d'un precurseur amyloide de la maladie d'alzheimer, stimulee par activation des recepteurs d'acetylcholine muscarinique
CA2333951C (fr) * 1998-06-01 2012-02-28 Ortho-Mcneil Pharmaceutical, Inc. Methode de traitement de troubles neurodegeneratifs
FR2793245B1 (fr) * 1999-05-05 2002-10-11 Adir Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CA2661122A1 (fr) 2008-02-21
WO2008020131A1 (fr) 2008-02-21
EP2051994A1 (fr) 2009-04-29
BRPI0715890A2 (pt) 2015-06-16
NO20090769L (no) 2009-02-18
MX2009001591A (es) 2009-02-23
JP2010505089A (ja) 2010-02-18
EA200900149A1 (ru) 2009-12-30
FR2905009A1 (fr) 2008-02-22
KR20090047532A (ko) 2009-05-12
AU2007285666A1 (en) 2008-02-21
US20100197740A1 (en) 2010-08-05
CN101506231A (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
MA30648B1 (fr) Methode de criblage de composes aux proprietes anti-amyloide.
WO2007011834A3 (fr) Composes et procede pour diagnostiquer et traiter les maladies associees aux amyloides
Austin et al. Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide
Tarutani et al. Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43
EA016193B9 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их использования
WO2002074240A3 (fr) Diagnostic et traitement d'une maladie ou d'une affection neurologique se fondant sur un anticorps anti-amyloide
Cai et al. Panoptic vDISCO imaging reveals neuronal connectivity, remote trauma effects and meningeal vessels in intact transparent mice
Deckert et al. Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity
WO2005098433A3 (fr) Methodes diagnostiques de la maladie d'alzheimer
Wellman et al. Aberrant accumulation of age-and disease-associated factors following neural probe implantation in a mouse model of Alzheimer’s disease
Tessa et al. A novel KIF5A/SPG10 mutation in spastic paraplegia associated with axonal neuropathy
Khedr et al. TMS excitability study in essential tremor: Absence of gabaergic changes assessed by silent period recordings
Sahara et al. Tau oligomers as potential targets for early diagnosis of tauopathy
Kaštelan et al. Eyes as the window to the brain-a key to the schizophrenia puzzle
Miller et al. Dorsal motor nucleus of vagus protein aggregates in Lewy body disease with autonomic dysfunction
Aydin et al. Microsurgical anatomy of middle longitudinal fasciculus
Kovatsi et al. Cerebrospinal fluid levels of calcium, magnesium, copper and zinc in patients with Alzheimer's disease and mild cognitive impairment.
Assefi et al. Level of CSF GAP-43 and white matter microstructural changes in Alzheimer's disease
Ventrano Histologic analysis of cortical tissue from patients with post traumatic stress disorder and chronic traumatic encephalopathy
Payne et al. Behavioral disturbances in dementia as a factor in institutionalization
MacDonald Borrelia invasion of brain pyramidal neurons and biofilm Borrelia plaques in neuroborreliosis dementia with Alzheimer’s phenotype
Uryu et al. P2-250 Short-term accumulation of beta amyloid in axonal pathology following traumatic brain injury in human
Lajevardi et al. The effect of psychological factors on cognitive functions in stroke patients with chronic fatigue
Mavroudis et al. Neuropathological findings in essential tremor
Gonzalez et al. BPS2025-Asparagine to aspartate deamidation does not disrupt γD-crystallin stability and structure